Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Yandex and Lanit Group decide to sell their stakes in OpenYard

6/30/23 YNDX

Shareholders of OGK-2 approved dividends for 2022

6/30/23 OGKB

Shareholders of Nizhnekamskneftekhim approved dividends for 2022

6/30/23 NKNC

Shareholders of Transneft approved dividends for 2022

6/30/23 TRNFP

Shareholders of Tatneft approved dividends for 2022

6/30/23 TATN

Shareholders of Human Stem Cells Institute approved dividends for 2022

6/30/23 ABIO

HSCI will rebrand and change its name to Artgen Biotech

6/30/23 ABIO

Qiwi has completed first phase of restructuring

6/30/23 QIWI

Magnit continues to expand its MCosmetic network in Uzbekistan

6/30/23 MGNT

Board of Directors of Territorial Generating Company № 14 recommended that dividends be paid for 2023

6/30/23 TGKN